Switzerland hospital covid-19 testing patient Switzerland

Drug shows promise in 1st largely minority COVID-19 study

Reading now: 977
www.clickorlando.com

A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled Hispanics and Blacks.Switzerland-based Roche reported the results for tocilizumab, sold now as Actemra and RoActemra for treating rheumatoid arthritis and some other diseases.

The company said it would quickly publish the results, which have not yet been reviewed by independent scientists, and would speak with regulators about next steps.

The drug, given through an IV, tamps down a protein called interleukin-6 that’s often found in excess in COVID-19 patients. It failed in a previous study that tested it in people more severely ill.

Read more on clickorlando.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA